Serum AQP4-IgG and BCMA
The serum titers of AQP4-IgG were measured using live-cell-based assay after screening. Serum AQP4-IgG for all treated participants decreased after CT103A infusion, and was negative by 12 weeks in 7 of the 10 patients (70%), and by 6 months in 5 of the 6 patients (83%) (Fig. The serum BCMA levels significantly reduced (below lower limit of detection) within 1-month post-infusion, but gradually returned to baseline levels by 6 months (Fig. 